High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 196-204

  Hengzhuang, Wang ^a   Ciofu, Oana ^b   Yang, Liang ^c,e   Wu, Hong ^a,b,e   Song, Zhijun ^a   Oliver, Antonio ^d   Høibya, Niels ^a,b,f  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^e NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^f European Society for Clinical Microbiology and Infectious Diseases   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; COLISTIN; IMIPENEM;

ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM MUTANT; BIOFILM; CONCENTRATION RESPONSE; CONTROLLED STUDY; IN VITRO STUDY; INOCULATION; KINETICS; MAXIMUM PLASMA CONCENTRATION; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BIOFILMS; CEFTAZIDIME; COLONY COUNT, MICROBIAL; DIFFUSION CHAMBERS, CULTURE; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MUTATION; PLANKTON; PSEUDOMONAS AERUGINOSA; TIME FACTORS;

EID: 84872030717     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01393-12     Document Type: Article

References (49)

1. Ciofu O, Beveridge TJ, Kadurugamuwa J, Walther-Rasmussen J, Hoiby N. 2000. Chromosomal beta-lactamase is packaged into membrane vesicles and secreted from Pseudomonas aeruginosa. J. Antimicrob. Chemother. 45:9-13.
2. Gould IM, van der Meer JWM. 2007. Antibiotic policies: theory and practice, p 149-174. Springer Verlag, New York, NY.
3. Høiby N. 1974. Pseudomonas aeruginosa infection in cystic fibrosis. Relationship between mucoid strains of Pseudomonas aeruginosa and the humoral immune response. Acta Pathol. Microbiol. Scand. B Microbiol. Immunol. 82:551-558.
4. Høiby N. 2011. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 9:32-38. doi:10.1186/1741- 7015-9-32.
5. Andes D, Craig WA. 1998. Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy. Infect. Dis. Clin. North Am. 12:849-860.
6. Craig WA. 2001. Pharmacodynamics of antimicrobials: general concepts and applications. Antimicrobial pharmacodynamics in theory and clinical practice, p 1-22. Marcel Dekker, New York, NY.
7. Høiby N, Krogh Johansen H, Moser C, Song Z, Ciofu O, Kharazmi A. 2001. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect. 3:23-35.
8. Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T, Høiby N. 2010. Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 156:1108-1119.
9. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322.
10. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. 1998. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 280:295-298.
11. Tyson GW, Chapman J, Hugenholtz P, Allen EE, Ram RJ, Richardson PM, Solovyev VV, Rubin EM, Rokhsar DS, Banfield JF. 2004. Community structure and metabolism through reconstruction of microbial genomes from the environment. Nature 428:37-43.
12. Bagge N, Ciofu O, Skovgaard LT, Høiby N. 2000. Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal β-lactamase. APMIS 108:589-600.
13. Bagge N, Ciofu O, Hentzer M, Campbell JIA, Givskov M, Høiby N. 2002. Constitutive high expression of chromosomal beta-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob. Agents Chemother. 46:3406-3411.
14. Bagge N, Hentzer M, Andersen JB, Ciofu O, Givskov M, Høiby N. 2004. Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 48:1168-1174.
15. Bagge N, Schuster M, Hentzer M, Ciofu O, Givskov M, Greenberg EP, Høiby N. 2004. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production. Antimicrob. Agents Chemother. 48:1175-1187.
16. Ciofu O, Høiby N. 2007. Cystic fibrosis: coping with resistance, p 149-174. In Ciofu O, Høiby N, Gould IM, van der Meer, JWM (ed), Antibiotic policies: fighting resistance. Springer, New York, NY.
17. Hengzhuang W, Wu H, Ciofu O, Song Z, Hoiby N. 2012. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem on biofilm Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56:2683-2690.
18. Hengzhuang W, Wu H, Ciofu O, Song Z, Hoiby N. 2011. Pharmacokinetics/ pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 55:4469-4474.
19. Mueller M, de la Pena A, Derendorf H. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 48:369-377.
20. Nielsen EI, Viberg A, Lowdin E, Cars O, Karlsson MO, Sandstrom M. 2007. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob. Agents Chemother. 51:128-136.
21. Pankuch GA, Jacobs MR, Appelbaum PC. 1994. Study of comparative antipneumococcal activities of penicillin G, Rp-59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob. Agents Chemother. 38:2065-2072.
22. Brook I. 1989. Inoculum effect. Rev. Infect. Dis. 11:361-368.
23. Herrmann G, Yang LA, Wu H, Song ZJ, Wang HZ, Høiby N, Ulrich M, Molin S, Riethmuller J, Doring G. 2010. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J. Infect. Dis. 202:1585-1592.
24. Juan C, MoyÁ B, Pérez JL, Oliver A. 2006. Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level β-lactam resistance involves three AmpD homologues. Antimicrob. Agents Chemother. 50:1780-1787.
25. O'Callaghan CH, Morris A, Kirby SM, Shingler A. 1972. Novel method for detection of β-lactamases by using a chromogenic cephalosporin substrate. Antimicrob. Agents Chemother. 1:283-288.
26. Klausen M, Heydorn A, Ragas P, Lambertsen L, Aaes-Jorgensen A, Molin S, Tolker-Nielsen T. 2003. Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants. Mol. Microbiol. 48:1511-1524.
27. Frolund B, Palmgren R, Keiding K, Nielsen PH. 1996. Extraction of extracellular polymers from activated sludge using a cation exchange resin. Water Res. 30:1749-1758.
28. Amsterdam D. 2005. Susceptibility testing of antimicrobials in liquid media, p 61-143. In Lorian V (ed), Antibiotics in laboratory medicine, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
29. -/- mice. Antimicrob. Agents Chemother. 51:3677-3687.
30. Pedersen SS, Shand GH, Hansen BL, Hansen GN. 1990. Induction of experimental chronic Pseudomonas aeruginosa lung infection with Pseudomonas aeruginosa entrapped in alginate microspheres. APMIS 98:203-211.
31. Wu H, Song ZJ, Hentzer M, Andersen JB, Heydorn A, Mathee K, Moser C, Eberl L, Molin S, Høiby N, Givskov M. 2000. Detection of N-acylhomoserine lactones in lung tissues of mice infected with Pseudomonas aeruginosa. Microbiology 146:2481-2493.
32. Boulos L, Prévost M, Barbeau B, Coallier J, Desjardins R. 1999. LIVE/DEAD(R) BacLight(TM): application of a new rapid staining method for direct enumeration of viable and total bacteria in drinking water. J. Microbiol. Methods 37:77-86.
33. O'Toole GA, Kolter R. 1998. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol. Microbiol. 30:295-304.
34. Alhede M, Kragh KN, Qvortrup K, Allesen-Holm M, van Gennip M, Christensen LD, Jensen PØ, Nielsen AK, Parsek M, Wozniak D. 2011. Phenotypes of non-attached Pseudomonas aeruginosa aggregates resemble surface attached biofilm. PLoS One 6:e27943. doi:10.1371/journal.pone.0027943.
35. Heydorn A, Nielsen AT, Hentzer M, Sternberg C, Givskov M, Ersbøll BK, Molin S. 2000. Quantification of biofilm structures by the novel computer program COMSTAT. Microbiology 146:2395-2407.
36. Sternberg C, Tolker-Nielsen T. 2005. Growing and analyzing biofilms in flow cells. Curr. Protoc. Microbiol. Chapter 1:Unit 1B.2.
37. Craig WA. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
38. Mouton JW, Den Hollander J. 1994. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 38:931-936.
39. Mouton JW, Vinks AA, Punt NC. 1997. Pharmacokineticpharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob. Agents Chemother. 41:733-738.
40. Ciofu O, Tolker-Nielsen T. 2010. Antibiotic tolerance and resistance in biofilms, p 215-230. In Bjarnsholt T, Moser C, Jensen PO, Hoiby N (ed), Biofilm infections. Springer, New York, NY.
41. Nichols WW, Evans MJ, Slack MPE, Walmsley HL. 1989. The penetration of antibiotics into aggregates of mucoid and non-mucoid Pseudomonas aeruginosa. J. Gen. Microbiol. 135:1291-1303.
42. Moellering RC Jr, Eliopoulos GM, Sentochnik DE. 1989. The carbapenems: new broad spectrum beta-lactam antibiotics. J. Antimicrob. Chemother. 24(Suppl A):1-7.
43. Herzberg O, Moult J. 1987. Bacterial resistance to beta-lactam antibiotics: crystal structure of beta-lactamase from Staphylococcus aureus PC1 at 2.5 Å resolution. Science 236:694-701.
44. Fisher JF, Meroueh SO, Mobashery S. 2005. Bacterial resistance to β-lactam antibiotics: compelling opportunism, compelling opportunity. ChemInform 36. doi:10.1002/chin.200524267.
45. Dibdin GH, Assinder SJ, Nichols WW, Lambert PA. 1996. Mathematical model of β-lactam penetration into a biofilm of Pseudomonas aeruginosa while undergoing simultaneous inactivation by released β-lactamases. J. Antimicrob. Chemother. 38:757-769.
46. Hornby JM, Jensen EC, Lisec AD, Tasto JJ, Jahnke B, Shoemaker R, Dussault P, Nickerson KW. 2001. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl. Environ. Microbiol. 67:2982-2992.
47. Davies TA, Page MGP, Shang W, Andrew T, Kania M, Bush K. 2007. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:2621-2624.
48. Stevens DL, Van S, Bryant AE. 1993. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J. Infect. Dis. 167:1401-1405.
49. Li Z, Clarke AJ, Beveridge TJ. 1996. A major autolysin of Pseudomonas aeruginosa: subcellular distribution, potential role in cell growth and division and secretion in surface membrane vesicles. J. Bacteriol. 178:2479-2488.